Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eniluracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD known ✓ | Q12882 | 5/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eniluracil SCHEMBL37817 | 0.86 | DPYD (1.00) | DPYDALDH1A1GAAATAD2LMNA | |
| Uracil SCHEMBL1217600 | 0.76 | CRBN (0.74) | DPYDCRBNMMP2TP53ATAD2 | |
| Uracil SCHEMBL27874550 | 0.75 | CRBN (0.90) | DPYDCRBNMMP2ALDH1A1GAA | |
| Uracil SCHEMBL8235 | 0.75 | — | — | |
| Uracil SCHEMBL3798527 | 0.75 | CRBN (1.00) | DPYDCRBNMMP2ALDH1A1GAA | |
| Uracil SCHEMBL5089507 | 0.75 | — | — | |
| Thymine SCHEMBL574783 | 0.74 | ATAD2 (0.70) | DPYDCRBNMMP2ALDH1A1GAA | |
| Fluorouracil SCHEMBL16766745 | 0.74 | ALDH1A1 (0.70) | DPYDCRBNMMP2ALDH1A1GAA | |
| 5-Bromouracil SCHEMBL27980194 | 0.74 | CRBN (0.63) | DPYDCRBNMMP2ALDH1A1GAA | |
| Uracil SCHEMBL28405698 | 0.73 | CRBN (0.57) | DPYDCRBNMMP2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007525429-A | — | — | 2007-09-06 | — | — | JP | claimed |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | QLT USA, INC. | 2006-06-08 | — | — | US | claimed |
| EP-1622540-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004081196-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | QLT USA, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1622540-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004081196-A2 | FORMULATIONS FOR CELL- SCHEDULE DEPENDENT ANTICANCER AGENTS | QLT USA INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | CDC25A, CCNB1, CCNE1 | DPYD 371/4885CRBN 3737/4885MMP2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.